Michael has over 30 years of senior management, research and teaching experience in med-tech, life sciences and blue biotech. He has taught at universities in South Africa and the UK and has worked with organizations from start-ups to listed companies where he has developed in vitro diagnostic devices using chemistry, enzymology, lateral flow and GC-IMS. Michael has been developing antimicrobial agents for 25+ years and has achieved Orphan Drug Designation by the FDA for a first-in-class anti-virulence compound against Pseudomonas aeruginosa, with his most recent work in antimicrobials being Disperazol.
He holds a master’s degree in Law and PhDs in Anatomy and in Pharmaceutical Chemistry, is co-author on publications in the fields of drug development, diagnostics and food science and holds joint inventorship on various patents in the field of microbial control and diagnostics.
